On March 28, the US Food and Drug Administration (FDA) expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibitor therapy and are considered appropriate to delay taxane-based chemotherapy.

For more information, read the FDA announcement or the Novartis press release.

Posted on 4/8/25